Approval · Notice of Compliance 2540 · 2001
SEROQUEL: Notice of Compliance 2540
Issued June 20, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2540
- Date
- June 20, 2001
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strength
- Therapeutic class
- Antipsychotic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SEROQUEL | 02244107 | Marketed |
Medicinal ingredients
- QUETIAPINE FUMARATE 300 MG per TAB